Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77054.
Department of Chemistry, University of Iowa, Iowa City, IA 52245.
Microbiol Spectr. 2016 Nov;4(6). doi: 10.1128/microbiolspec.FUNK-0009-2016.
Many Fungi have a well-developed secondary metabolism. The diversity of fungal species and the diversification of biosynthetic gene clusters underscores a nearly limitless potential for metabolic variation and an untapped resource for drug discovery and synthetic biology. Much of the ecological success of the filamentous fungi in colonizing the planet is owed to their ability to deploy their secondary metabolites in concert with their penetrative and absorptive mode of life. Fungal secondary metabolites exhibit biological activities that have been developed into life-saving medicines and agrochemicals. Toxic metabolites, known as mycotoxins, contaminate human and livestock food and indoor environments. Secondary metabolites are determinants of fungal diseases of humans, animals, and plants. Secondary metabolites exhibit a staggering variation in chemical structures and biological activities, yet their biosynthetic pathways share a number of key characteristics. The genes encoding cooperative steps of a biosynthetic pathway tend to be located contiguously on the chromosome in coregulated gene clusters. Advances in genome sequencing, computational tools, and analytical chemistry are enabling the rapid connection of gene clusters with their metabolic products. At least three fungal drug precursors, penicillin K and V, mycophenolic acid, and pleuromutilin, have been produced by synthetic reconstruction and expression of respective gene clusters in heterologous hosts. This review summarizes general aspects of fungal secondary metabolism and recent developments in our understanding of how and why fungi make secondary metabolites, how these molecules are produced, and how their biosynthetic genes are distributed across the Fungi. The breadth of fungal secondary metabolite diversity is highlighted by recent information on the biosynthesis of important fungus-derived metabolites that have contributed to human health and agriculture and that have negatively impacted crops, food distribution, and human environments.
许多真菌具有发达的次生代谢。真菌物种的多样性和生物合成基因簇的多样化突出表明代谢变异的潜力几乎是无限的,这是药物发现和合成生物学的未开发资源。丝状真菌在殖民地球方面取得的大部分生态成功归功于它们能够将次生代谢物与穿透和吸收的生活方式协同部署。真菌次生代谢物具有生物活性,已被开发成救命药物和农用化学品。有毒代谢物,称为真菌毒素,污染了人类和牲畜的食物和室内环境。次生代谢物是人类、动物和植物真菌疾病的决定因素。次生代谢物在化学结构和生物活性方面表现出惊人的变化,但它们的生物合成途径具有许多关键特征。编码生物合成途径协同步骤的基因往往在染色体上紧密排列在核心调控基因簇中。基因组测序、计算工具和分析化学的进步使基因簇与其代谢产物的快速连接成为可能。至少有三种真菌药物前体,青霉素 K 和 V、麦角酸和截短侧耳素,已经通过各自基因簇在异源宿主中的合成重建和表达来生产。这篇综述总结了真菌次生代谢的一般方面以及我们对真菌如何以及为什么产生次生代谢物、这些分子如何产生以及它们的生物合成基因如何在真菌中分布的理解的最新进展。最近关于对人类健康和农业有贡献的重要真菌衍生代谢物生物合成的信息突出了真菌次生代谢物多样性的广度,这些代谢物对作物、食物分布和人类环境产生了负面影响。